Maintaining blood flow in the extracorporeal circuit: haemostasis and anticoagulation
- PMID: 7560483
- DOI: 10.1007/BF02425162
Maintaining blood flow in the extracorporeal circuit: haemostasis and anticoagulation
Abstract
Objectives: To review the methods and developments in maintaining extracorporeal circuits in critically ill patients.
Design: The review includes details of the pathophysiological processes of haemostasis and coagulation in critically ill patients, methods of maintaining blood flow in the extracorporeal circuit and methods of monitoring anticoagulation agents used.
Setting: Information is relevant to the management of critically ill patients requiring extracorporeal renal and respiratory support and cardiopulmonary bypass.
Conclusions: Heparin is the mainstay of anticoagulation for the extracorporeal circuit although the complex abnormalities of the coagulation system in critically ill patients are associated with a considerable risk of bleeding. Alternative therapeutic agents and physical strategies (prostacyclin, low molecular weight heparin, sodium citrate, regional anticoagulation, heparin bonding and attention to circuit design) may reduce the risk of bleeding but expense and difficulty in monitoring are disadvantages.
Similar articles
-
Anticoagulation management associated with extracorporeal circulation.Best Pract Res Clin Anaesthesiol. 2015 Jun;29(2):189-202. doi: 10.1016/j.bpa.2015.03.005. Epub 2015 Mar 31. Best Pract Res Clin Anaesthesiol. 2015. PMID: 26060030 Review.
-
Anticoagulation in Critically Ill Adults during Extracorporeal Circulation.Hamostaseologie. 2021 Aug;41(4):294-306. doi: 10.1055/a-1389-8216. Epub 2021 Apr 15. Hamostaseologie. 2021. PMID: 33860514 Review.
-
[Anticoagulation of extracorporeal circuit in critically ill patients].G Ital Nefrol. 2007 Jan-Feb;24(1):34-42. G Ital Nefrol. 2007. PMID: 17342691 Italian.
-
Hemostasis and thrombosis in continuous renal replacement treatment.Semin Thromb Hemost. 2015 Feb;41(1):91-8. doi: 10.1055/s-0034-1398384. Epub 2015 Jan 15. Semin Thromb Hemost. 2015. PMID: 25590526 Review.
-
Coagulation and anticoagulation in extracorporeal membrane oxygenation.Artif Organs. 1999 Nov;23(11):979-83. doi: 10.1046/j.1525-1594.1999.06451.x. Artif Organs. 1999. PMID: 10564301
Cited by
-
The effect of specialized continuous renal replacement therapy team in acute kidney injury patients treatment.Yonsei Med J. 2015 May;56(3):658-65. doi: 10.3349/ymj.2015.56.3.658. Yonsei Med J. 2015. PMID: 25837170 Free PMC article.
-
Integration of transcriptomics and metabolomics reveals the molecular mechanisms underlying the effect of nafamostat mesylate on rhabdomyolysis-induced acute kidney injury.Front Pharmacol. 2022 Nov 29;13:931670. doi: 10.3389/fphar.2022.931670. eCollection 2022. Front Pharmacol. 2022. PMID: 36532745 Free PMC article.
-
What are the anticoagulation options for intermittent hemodialysis?Nat Rev Nephrol. 2011 Jul 5;7(9):499-508. doi: 10.1038/nrneph.2011.88. Nat Rev Nephrol. 2011. PMID: 21727925 Review.
-
Building and validation of a prognostic model for predicting extracorporeal circuit clotting in patients with continuous renal replacement therapy.Int Urol Nephrol. 2014 Apr;46(4):801-7. doi: 10.1007/s11255-014-0682-5. Epub 2014 Mar 18. Int Urol Nephrol. 2014. PMID: 24638211
-
Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?Intensive Care Med. 2006 Feb;32(2):188-202. doi: 10.1007/s00134-005-0044-y. Epub 2006 Feb 2. Intensive Care Med. 2006. PMID: 16453140
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical